Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers
Seminars in Cancer Biology · 2025-07 · 112 · 150-166
DOI: 10.1016/j.semcancer.2025.04.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Cancer Biology, 2025-07. Verfasst von Yuki Fujii und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology Science, University of Oklahoma Health Sciences, Oklahoma City, OK 73014, USA. Hauptthemen laut MEDLINE: Cathepsins, Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 190 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, U.S. Department of Defense.
Abstract (Originalsprache)
Cathepsins, a group of lysosomal peptidases, have traditionally been recognized as tumor facilitators. Recent research, however, highlights their critical role in orchestrating cancer and the tumor microenvironment (TME). Primality, cathepsins degrade extracellular matrix, enabling cancer cells to invade and metastasize, while also promoting vascular endothelial infiltration and subsequent angiogenesis. Additionally, cathepsins boost fibroblast growth, thereby supporting tumor progression. More importantly, cathepsins are pivotal in modulating immune cells within the TME by regulating their recruitment, antigen processing and presentation, differentiation, and cell death, primarily contributing to immune suppression. Given their overexpression in tumors and elevated levels in the circulation of cancer patients, it is crucial to consider the systemic effects of cathepsins. Although the comprehensive role of cathepsins in cancer patients' bodies remains underexplored, they likely influence systemic immunity and inflammation, cellular metabolism, muscle wasting, and distant metastasis through their unique proteolytic functions. Notably, cathepsins also confer resistance to chemoradiotherapy by rewriting the cellular profile within the TME. In this context, promising results are emerging from studies combining cathepsin inhibitors with conventional therapies to suppress tumor development effectively. This review aims to decipher the cathepsin-driven networks within cancer cells and the TME, detailing their contribution to chemoradioresistance by reshaping both micro- and macroenvironments. Furthermore, we explore current and future perspectives on therapies targeting cathepsins' interactions, offering insights into innovative treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology Science, University of Oklahoma Health Sciences, Oklahoma City, OK 73014, USA.
- Department of Oncology Science, University of Oklahoma Health Sciences, Oklahoma City, OK 73014, USA; Department of Pathology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA.
- Department of Oncology Science, University of Oklahoma Health Sciences, Oklahoma City, OK 73014, USA; Department of Microbiology and Immunology, University of Oklahoma Health Sciences, Oklahoma City, OK 73104, USA; Depa…
Förderung
- NCI NIH HHS
- National Institutes of Health
- U.S. Department of Defense
Zitieren
APA
Fujii, Y., Asadi, Z., & Mehla, K. (2025). Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers. Seminars in Cancer Biology, 112, 150-166. https://doi.org/10.1016/j.semcancer.2025.04.001
Vancouver
Fujii Y, Asadi Z, Mehla K. Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers. Seminars in Cancer Biology. 2025;112:150-166. doi:10.1016/j.semcancer.2025.04.001
BibTeX
@article{Fujii2025,
author = {Fujii, Yuki and Asadi, Zahra and Mehla, Kamiya},
title = {Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers},
journal = {Seminars in Cancer Biology},
year = {2025},
volume = {112},
pages = {150--166},
doi = {10.1016/j.semcancer.2025.04.001}
}
EUVIMED